News

Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology

Shark antibody technology has potential to deliver therapeutics across previously impermeable BBB 26 January 2017 – PHILADELPHIA, USA & STEVENAGE, UK: Ossianix Inc., which has generated a world leading platform for delivering biotherapeutic products into the CNS using the highly versatile single domain VNAR antibody from the shark, has received a milestone payment from Lundbeck following the successful completion of the objectives from a 2014 research collaboration agreement.  The project…

Read more

Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics 16 December 2014

PHILADELPHIA, PA: Ossianix, Inc. today announced an expansion and extension of its strategic research collaboration with H. Lundbeck A/S (Lundbeck). This collaboration follows a previous equity investment in 2012 and prior research collaboration in 2013. The collaboration will use Ossianix’s innovative single domain antibody platform based on the shark VNAR structure to deliver next generation CNS biotherapeutics. Ossianix’s has developed a novel Blood Brain Barrier (BBB) targeting technology for the…

Read more

Ossianix Announces Strategic Research Collaboration with Lundbeck

Ossianix, Inc. today announced a strategic research collaboration with Lundbeck A/S. This collaboration follows a previous investment in 2012. The collaboration uses Ossianix’s innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects.

Read more

Ossianix Announces Lundbeck Investment

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck’s investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix’s proprietary single domain antibody platform modeled on the shark vNAR structure.

Read more